Opinion
New weight loss drugs raise questions of access, costs
New, popular injectable weight loss drugs — GLP-1 drugs — are highly effective at reducing obesity and, probably, the health risks posed by obesity. Yet the drugs are so expensive that insurers are often choosing between two bad options: restricting access or raising consumer costs.
Weight-loss drugs may be no obesity silver bullet
Sir Keir Starmer and his health secretary have been lauding the potential of the new generation of weight-loss drugs. Given as regular injections, the treatments – Wegovy and Mounjaro – mimic a hormone that makes people less hungry.
Weight loss drugs like Ozempic may help reduce overdose risks: Study
A study suggests that weight loss medications like Ozempic may help reduce the risk of overdose and alcohol intoxication in people with substance use disorders.
Could Weight-Loss Drugs Help Get People Back to Work? The U.K. Wants to Find Out.
The British government announced a multimillion dollar pharmaceutical partnership with Eli Lilly, including a trial that will study the impact of a weight-loss drug on work and productivity.
New drug approach could underpin future weight loss therapies, study indicates
Therapies that deliver hydrogen sulfide to cells could one day become the basis of new treatments for obesity and related diseases, new research has concluded.
Opinion
Reher: Counterfeit weight-loss drug crisis looms
Bad actors are using online ads, social media and bootleg ingredients to sell fake, inaccurate and harmful versions of these drugs, nearly indistinguishable from the real thing.
Ozempic shows promise for treating alcohol and drug abuse, study finds
The weight-loss drugs are linked with reduced rates of excess drinking and opioid overdoses, suggesting they may tamp down substance use cravings too.
Weight-loss drugs may reduce opioid and alcohol abuse by up to 50%, study finds
Weight-loss drugs such as Ozempic, made by Denmark’s Novo Nordisk, can reduce rates of opioid and alcohol abuse by up to 50%, according to a new study that supports expectations the drugs can offer greater benefits than just weight and diabetes management.
Weight-Loss Drugs Cut Drug and Alcohol Abuse, According to New Study
Drugs such as Novo Nordisk’s Ozempic can cut drug and alcohol abuse by up to 50%, a study found, adding to mounting evidence that the drugs yield health benefits beyond diabetes and weight loss.
Weight loss drugs could help with alcohol, opioid addiction, study says
Drugs​ like Mounjaro and Ozempic, which many use for weight loss,​​ may also help patients suffering from addiction, according to a new study.
Weight loss drugs may help lower overdoses, alcoholism: Study
Researchers analyzed 1.3 million health records and found Ozempic, Mounjaro could lower rates of drug and alcohol overdoses.
The Breakthrough Drug to Conquer Addiction: Ozempic?
Early data suggests GLP-1 drugs, renowned for their ability to assist in weight loss, may have a powerful effect on treating ...
Adolescents treated for obesity with GLP-1 drugs had lower risk of suicidal thoughts, study finds
A review of the medical records of thousands of adolescents treated for obesity found that kids who received the GLP-1 ...
Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names
The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's ...
Ozempic boasts surprising mental health benefits for teens with obesity: new research
This research contradicts previous concerns about the potential of drugs like Ozempic to trigger suicidal ideation and ...
News Medical on MSN3d
Expanding access to GLP-1 weight-loss drugs could save thousands of lives
Researchers estimate that expanding access to weight-loss drugs could save over 50,000 lives annually, reducing obesity rates ...
Amgen’s stock falls as analyst warns that hype around obesity drug is baked in
Truist analyst Srikripa Devarakonda backs away from bullish call as competition mutes potential for biotech’s drug pipeline.
The ‘Peak Obesity’ Illusion
America’s obesity rate looks to be plateauing—again.
STAT1d
Pharmalittle: We’re reading about a new CVS chief, obesity meds cutting overdoses, and more
CVS Health named David Joyner as its new chief, succeeding Karen Lynch at the helm of the struggling healthcare giant ...